

CryoLife, Inc. Announces Baylor College of Medicine Animal Study Supports Use of BioGlue(R) in Phrenic Nerve Environment

November 19, 2001

CryoLife, Inc. Announces Baylor College of Medicine Animal Study Supports Use of BioGlue(R) in Phrenic Nerve Environment



CryoLife, Inc. Announces Baylor College of Medicine Animal Study Supports Use of BioGlue(R) in Phrenic Nerve Environment

[PR Newswire : PR Newswire · Rcvd: 2001-11-19T15:49:12-05:00]

ATLANTA, Nov. 19 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a life- science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopaedic reconstruction grafts, and surgical adhesives, today announced a recent study by Baylor College of Medicine demonstrates that a barrier of chlorhexidine gluconate gel, such as "Surgilube," protected the phrenic nerve against acute injury from BioGlue surgical adhesive. The study concluded, "This simple protective strategy allows BioGlue to be safely applied to vessels near nerves."

Kirby S. Black, Ph.D., Senior Vice President of Research and Development of CryoLife, noted, "This study by Baylor College of Medicine, demonstrates the versatility of BioGlue surgical adhesive. To date, BioGlue has been used in various procedures involving more than 40,000 individuals with no reports of nerve damage from exposure to BioGlue."

Founded in 1984, CryoLife, Inc., is the leader in the development and commercialization of implantable living human tissues for use in cardiovascular, vascular and orthopaedic surgeries throughout the United States and Canada. The Company's BioGlue surgical adhesive is approved as an adjunct for acute thoracic aortic dissections under HDE regulations in the United States and is CE marked in the European Community and approved in Canada and Australia for use in vascular and pulmonary sealing and repair.

This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes regarding future occurrences. Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These future events may not occur when expected, if at all, and are subject to various risks and uncertainties. Such risks and uncertainties include the possibility that the use of chlorhexidine gluconate gel may not prove efficacious as a strategy for preventing nerve damage.

For additional information about the company, visit CryoLife's web site: <http://www.cryolife.com> .

Contact: Roy Vogeltanz

Vice President, Corporate Communications
(800) 438-8285

MAKE YOUR OPINION COUNT - [Click Here](#)
<http://tbutton.prnewswire.com/prn/11690X51367798>

SOURCE CryoLife, Inc.

CONTACT: Roy Vogeltanz, Vice President, Corporate Communications of CryoLife, Inc., +1-800-438-8285/